EQS News: Evotec has developed a strong Forschritte in a strategic partnership with Bristol Myers Squibb in the area of Protein Degradation Page 1

EQS News: Evotec SE / Schlagwort(e): Sontiges
Evotec has developed a strong forerunner in a strategic partnership with Bristol Myers Squibb in the area of Protein Degradation

13.08.2024 / 07:30 CET/CEST
Inhaling the Mitteilung is the Issuer / Herausgeber responsible.

Want to learn more about the discovery of the Molecular Glue Degraders Pipeline?
Leistungs- und programmabhängige Zahlungen und Evotec in Höhe von insgesamt 75 Mio. US$

Hamburg, August 13, 2024:
Evotec SE (Frankfurter Wertpaperbörse: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) has developed a strong position in Bristol Myers Squibb’s strategic partnerships in the development of a pipeline with molecular adhesives. Performance and program-dependent follow-up individual payments in the amount of approximately US$ 75 million and Evotec aus.

In 2018, the partnership with Evotecs began with its powerful Multi-Omics Screening and Analysis Capabilities with Bristol Myers Squibb’s Cereblon E3 Ligase Modulators (“CELMoDs”) branching library. Since 2022, the collaboration has been expanded with Ziel, a new pipeline for molecular adhesive degraders has been developed, which has delivered the best results on highly qualified targets in oncology. The powerful and program-dependent Success Building Evotecs combines the same pipeline and programs further.

Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, commented: „Bristol Myers Squibb is developed in Bereich Molecular Glue Degraders, one of the most exciting new therapeutic modalities. If we work systematically and industrially, pan-omics based analyses will recover a pipeline and molecular degraders, which are applied to high targets. The Breite and Tiefe Our Pipeline will ensure that more first-class products will be brought to the market and with good positioning, will be one of our products.“